Elevar Therapeutics receives FDA approval for Lyrfigtu as second-line treatment for bile duct cancer

The U.S. Food and Drug Administration has approved Elevar Therapeutics' drug Lyrfigtu as a second‑line option for patients with bile duct cancer who meet specific criteria.

Bile duct cancer is diagnosed in roughly 8,000 people in the United States each year, making treatment options limited for many patients.

This approval represents Elevar's first FDA clearance, marking a significant milestone for the company and expanding therapeutic choices for this rare cancer.

The decision was based on data submitted by Elevar, though the agency's detailed rationale was not disclosed in the brief report.